Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
abiraterone acetate
pharmacodynamics
pharmacogenetics
prostate cancer
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
15 Feb 2023
15 Feb 2023
Historique:
received:
21
12
2022
revised:
31
01
2023
accepted:
08
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Abiraterone acetate (AA) is the first-in-class of drugs belonging to the second-generation of agents inhibiting androgen neosynthesis in advanced prostate cancer. A cumulative experience attests that germinal gene polymorphisms may play a role in the prediction of anticancer agent pharmacodynamics variability. In the present prospective, multicentric study, gene polymorphisms of CYP17A1 (AA direct target) and the androgen transporter genes SLCO2B1 and SLCO1B3 (potential modulators of AA activity) were confronted with AA pharmacodynamics (treatment response and toxicity) in a group of 137 advanced prostate cancer patients treated in the first line by AA. The median follow-up was 56.3 months (95% CI [52.5-61]). From multivariate analysis, rs2486758 C/C (
Identifiants
pubmed: 36839973
pii: pharmaceutics15020651
doi: 10.3390/pharmaceutics15020651
pmc: PMC9959353
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Janssen (France)
ID : N/A
Références
N Engl J Med. 2010 Jul 8;363(2):166-76
pubmed: 20647212
Lancet. 2022 Apr 30;399(10336):1695-1707
pubmed: 35405085
Cancer Chemother Pharmacol. 2020 Oct;86(4):527-533
pubmed: 32945940
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Lancet Oncol. 2022 Oct;23(10):1297-1307
pubmed: 36063830
Future Oncol. 2018 Feb;14(5):431-442
pubmed: 29350549
Reprod Biomed Online. 2021 Nov;43(5):941-951
pubmed: 34538754
Int J Mol Sci. 2016 Jul 09;17(7):
pubmed: 27409606
Prostate. 2011 Aug 1;71(11):1167-77
pubmed: 21656827
Br J Clin Pharmacol. 2006 Jul;62(1):35-46
pubmed: 16842377
J Clin Oncol. 2011 Jun 20;29(18):2565-73
pubmed: 21606417
Nat Med. 2022 Apr;28(4):617-620
pubmed: 35440715
J Clin Oncol. 2022 Jun 1;40(16):1721-1731
pubmed: 35324346
Clin Pharmacokinet. 2022 Nov;61(11):1495-1517
pubmed: 36180817
BJU Int. 2008 Feb;101(4):492-6
pubmed: 17986287
J Urol. 2016 Oct;196(4):1112-6
pubmed: 27150425
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406564
J Clin Endocrinol Metab. 2012 May;97(5):E852-7
pubmed: 22419734
Mol Cancer Ther. 2019 Mar;18(3):726-729
pubmed: 30587554
Clin Cancer Res. 2004 Jan 15;10(2):440-8
pubmed: 14760063
Clin Cancer Res. 2022 Nov 14;28(22):4917-4925
pubmed: 36088616
Prostate Cancer Prostatic Dis. 2022 Dec 1;:
pubmed: 36456698
Prostate Cancer Prostatic Dis. 2004;7(4):333-7
pubmed: 15477877
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951